Immunic Inc Stock Price, News & Analysis

Immunic, Inc. (Nasdaq: IMUX) announces its participation in multiple scientific and investor conferences in September 2024. Key events include:

1. MS R&D Day on September 10, featuring discussions on vidofludimus calcium (IMU-838) for MS treatment.

2. 40th ECTRIMS Congress (Sept 18-20) with presentations on vidofludimus calcium's impact on MS.

3. DMDG 50th Open Meeting (Sept 2-4) showcasing pharmacokinetics study results of vidofludimus calcium.

4. 20th International Celiac Disease Symposium (Sept 5-7) presenting data on IMU-856 for celiac disease treatment.

5. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept 17-19) featuring a fireside chat with CEO Daniel Vitt.

These events highlight Immunic's progress in developing treatments for chronic inflammatory and autoimmune diseases.

Immunic, Inc. (IMUX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Appointment of Jason Tardio as Chief Operating Officer and President, bringing MS drug commercialization experience.

2. Strengthened Board of Directors with Simona Skerjanec, a senior pharmaceutical executive.

3. Phase 3 ENSURE trials in Relapsing MS and Phase 2 CALLIPER trial in Progressive MS remain on track.

4. Q2 2024 R&D expenses decreased to $18.3 million from $21.2 million in Q2 2023.

5. Net loss for Q2 2024 was $21.4 million, or $0.21 per share.

6. Cash and cash equivalents of $79.7 million as of June 30, 2024, expected to fund operations into Q3 2025.

7. Top-line data from Phase 2 CALLIPER trial expected in April 2025.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, has announced that it will release its financial results for the second quarter ended June 30, 2024, along with a corporate update, on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a webcast at 8:00 am ET on the same day to discuss the results.

Interested parties can register for the webcast in advance through the provided link or on Immunic's website. An archived replay of the webcast will be available approximately one hour after its completion on the company's website.

Immunic, Inc. (Nasdaq: IMUX) has appointed Simona Skerjanec, M.Pharm, MBA, to its board of directors, effective July 22, 2024. Skerjanec brings nearly three decades of global pharmaceutical experience, particularly in brain health and drug development. She previously served as Senior Vice President, Global Head Neuroscience and Rare Diseases at Roche, where she led the successful commercial launch of Ocrevus®, a blockbuster multiple sclerosis (MS) therapy.

This appointment follows the recent hiring of Jason Tardio as Immunic's new Chief Operating Officer and President. The company is strengthening its leadership as it approaches multiple late-stage readouts for vidofludimus calcium in MS over the next two years. Skerjanec's expertise is expected to be valuable in potentially bringing this oral drug candidate to market and achieving commercial success.

Immunic announced the appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024. Tardio, a former executive at Novartis and Biogen, brings extensive experience in MS drug commercialization. He will lead efforts to launch vidofludimus calcium, an oral treatment for relapsing and progressive MS.

Additionally, Werner Gladdines has been promoted to Chief Development Officer. He previously served as Vice President, Program Management & Clinical Development Operations. Gladdines will now assume greater strategic and operational responsibilities for Immunic's clinical operations.

Tardio's notable achievements include launching successful MS drugs and leading commercial businesses. His expertise is expected to significantly aid Immunic as it approaches the completion of phase 3 trials for vidofludimus calcium and prepares for potential partnerships.

Immunic (Nasdaq: IMUX), a biotechnology company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, announced its participation in key industry and scientific conferences in June 2024. The company will present at the BIO International Convention in San Diego, California, from June 3-6, with Jessica Breu, VP of Investor Relations and Communications, presenting on June 4 at 11:00 am PDT. Immunic's management will engage in partnering activities at this event. Additionally, Werner Gladdines, VP of Program Management and Clinical Development Operations, will join a panel discussion at the Pharmaceutical Contract Management Group (PCMG) Assembly in Den Haag, The Netherlands, from June 5-7. His panel, 'Spin the Wheel of Collaboration!', is scheduled for June 6 at 12:05 pm CEST.

Immunic, Inc. reported Q1 2024 financial results, highlighting a three-tranche private placement of up to $240 million to extend cash runway, received a fourth US patent for MS treatment, and is progressing with phase 3 ENSURE trials in RMS and phase 2 CALLIPER trial in PMS. The company aims to position vidofludimus calcium as the first oral treatment for MS, while also advancing IMU-856 for gastrointestinal disorders.

Immunic, Inc. (Nasdaq: IMUX) will be participating in various investor and scientific conferences in May, presenting data from clinical trials of their small molecule therapies targeting chronic inflammatory and autoimmune diseases. The conferences include Bio€quity Europe, Digestive Disease Week, The Consortium of Multiple Sclerosis Centers, and the National Congress of Neurology. Key presentations will focus on the phase 1b clinical trial of IMU-856 for celiac disease and the phase 2 CALLIPER trial of vidofludimus calcium for multiple sclerosis.

Immunic, Inc., a biotechnology company focused on developing small molecule therapies for chronic inflammatory and autoimmune diseases, is set to announce its financial results for the first quarter ending March 31, 2024, along with a corporate update on May 8, 2024. A webcast will be held at 8:00 am ET on the same day. Participants can register in advance on the company's website to join the webcast.